Addex Therapeutics AAQS 2025

Addex Therapeutics làm gì?

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.